Citius Oncology (CTOR) risk factors
Item 1A of every Citius Oncology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors50 risks2 new4 dropped14 reworded
Citius Oncology faces a going concern warning, with sufficient capital to fund operations only through March 2026. The company depends entirely on the successful commercial launch and sales of its single approved product, LYMPHIR. Market uptake of LYMPHIR may be limited by small target populations, pricing, and third-party reimbursement.
Filed Dec 23, 2025 - FY2024 10-K risk factors52 risks
Citius Oncology is entirely dependent on the commercial success and funding of its sole approved product, LYMPHIR, which gained FDA approval in August 2024. The company faces significant financial pressures, including a history of net losses, the need for substantial additional capital, and milestone obligations totaling millions to Eisai and Dr. Reddy's. Operations rely heavily on third-party manufacturers, outsourced commercial partners, and shared services with Citius Pharma, which owns approximately 92.3% of its common stock.
Filed Dec 27, 2024